Potential new drug for Pancreatic Cancer

Revolution Medicines has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to two of its investigational drugs: daraxonrasib and elironrasib. These designations highlight the promise of these therapies for patients with cancers driven by specific RAS mutations—an area of significant unmet medical need.
• Daraxonrasib is a multi-selective KRAS inhibitor granted Breakthrough Therapy Designation for previously treated, metastatic pancreatic ductal adenocarcinoma (PDAC) with KRAS G12 mutations. This decision is based on early clinical data suggesting substantial improvement over existing therapies. Over 90% of PDAC patients have RAS mutations, with the majority bearing KRAS G12 variants. A global Phase 3 trial (RASolute 302) is ongoing, with results expected in 2026.
• Elironrasib is a selective KRAS G12C inhibitor awarded Breakthrough Therapy Designation for previously treated non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. Recent data highlighted good safety and promising efficacy in patients who had previously received chemotherapy and immunotherapy, but not a KRAS G12C inhibitor.
Breakthrough Therapy Designation expedites development and regulatory review for drugs showing preliminary evidence of significant clinical improvement in serious or life-threatening conditions.
The company has stated that these achievements underscore both the urgent need for new RAS-targeted cancer treatments and the potential of their emerging pipeline. Revolution Medicines has also secured a $2 billion funding agreement with Royalty Pharma to support clinical development and commercialization efforts.
These recent FDA designations reinforce Revolution Medicines’ leadership in developing new options for cancers historically associated with poor outcomes and few treatment alternatives.